Related Experiment Video

Updated: Sep 3, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway

Giovanni Tossetta1, Daniela Marzioni2

  • 1Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy; Clinic of Obstetrics and Gynaecology, Department of Clinical Sciences, Università Politecnica delle Marche, Salesi Hospital, Azienda Ospedaliero Universitaria, Ancona, Italy.

Pharmacological Research
|July 28, 2022
PubMed

Insights

Natural and synthetic compounds can modulate the NRF2/KEAP1 pathway to overcome chemoresistance in ovarian cancer. This research explores how targeting this pathway enhances chemotherapy effectiveness against this deadly gynecologic malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian cancer is a dangerous gynecologic malignancy with high fatality and relapse rates, often due to chemoresistance.
  • Oxidative stress is implicated in cancer development and progression.
  • Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that protects cells from oxidative damage by inducing antioxidant enzymes.

Purpose of the Study:

  • To review the current literature on natural and synthetic compounds that modulate the NRF2/KEAP1 pathway in ovarian cancer.
  • To investigate the role of NRF2 activation in chemoresistance development in ovarian cancer.
  • To explore how modulating the NRF2/KEAP1 pathway can impact chemotherapy response.

Main Methods:

  • Literature review of in vitro studies on ovarian cancer models.
  • Analysis of compounds targeting the NRF2/KEAP1 pathway.
  • Examination of the effects of NRF2 modulation on chemoresistance.

Main Results:

  • NRF2 activation in cancer cells contributes to chemoresistance by counteracting drug-induced oxidative stress.
  • Natural and synthetic compounds can modulate the NRF2/KEAP1 pathway.
  • Modulation of this pathway by compounds can alter chemotherapy response in ovarian cancer cells.

Conclusions:

  • Targeting the NRF2/KEAP1 pathway with specific compounds presents a potential strategy to overcome chemoresistance in ovarian cancer.
  • Further research into these compounds could lead to improved therapeutic approaches for ovarian cancer patients.
Keywords:
Ailanthone (PubChem CID: 72965)Apatinib (PubChem CID: 11315474)ChemotherapyCisplatinClofibrate (PubChem CID: 2796)CompoundsDexamethasone (PubChem CID: 5743)Diosmetin (PubChem CID: 5281612)Erastin (PubChem CID: 11214940)Genistein (PubChem CID: 5280961)Luteolin (PubChem CID: 5280445)NRF2Ovarian CancerRRx-001 (PubChem CID: 15950826)SignalingSulforaphane (PubChem CID: 5350)

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K